In a nutshell This study aimed to investigate the effectiveness of allogeneic hemopoietic stem cell transplant (alloHSCT) in patients with unresponsive acute myeloid leukemia. This study concluded that alloHSCT is the best treatment option for these patients. Some background Patients with unresponsive acute myeloid leukemia (AML) are those...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Searching for patients to try a new therapy for non-responsive leukemia/lymphoma after stem-cell transplant.
In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive leukemia/lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with...
Read MoreEffectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia
In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...
Read MoreLooking for patients with relapsed or unresponsive lymphoma to test a cell therapy
In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read MoreCombining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive mantle cell lymphoma (MCL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in these patients. Some background Mantle cell...
Read MoreSearching for patients with advanced melanoma to trial a new treatment combination
In a nutshell This trial aims to look at how safe and effective a new combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda). The main outcome measured will be the number of patients who respond to treatment, and to what extent they respond. This study is being conducted in Spain, Sweden, and the United States. The details...
Read MoreLooking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment
In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...
Read MoreLooking for patients with relapse/unresponsive lymphoma to test a treatment combination
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read MoreLooking for patients with relapsed or refractory lymphoma to test a cell therapy
In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read MoreEvaluating ibrutinib plus nivolumab for relapsed or refractory CLL
In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for...
Read MoreRituximab to treat unresponsive chronic lymphocytic leukemia in a real-world setting
In a nutshell This study examined the safety and effectiveness of rituximab (Rituxan) to treat relapsed or unresponsive chronic lymphocytic leukemia (CLL) in a real-world setting. Authors concluded that rituximab was safe and effective in these patients. Some background Chronic lymphocytic leukemia is a cancer of the immune system. It...
Read MoreEvaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma
In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...
Read More